Salloum I M, Cornelius J R, Thase M E, Daley D C, Kirisci L, Spotts C
Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, PA 15213, USA.
Psychopharmacol Bull. 1998;34(1):111-5.
The aim of this open-label pilot study was to evaluate the utility of naltrexone (50 mg per day) in decreasing alcohol use and to examine its impact on depressive symptoms among depressed alcoholics who have failed to abstain from alcohol use despite treatment with a selective serotonin reuptake inhibitor (SSRI). Fourteen ambulatory care patients, aged 18 to 65 years, with DSM-III-R comorbid diagnoses of alcohol dependence and major depressive disorder, who failed to abstain despite treatment with an antidepressant medication were enrolled in the study. Patients were followed for 12 weeks with weekly assessment of drinking behavior, depressive symptoms, functioning, alcohol craving, and side effects. The results of this study indicated a significant decrease in alcohol use and in urges to drink alcohol in the presence of the usual triggers. There was also a trend suggesting improvement in depressive symptoms and overall functioning. Naltrexone was well tolerated, with mild side effects reported at the onset of treatment.
这项开放标签的试点研究旨在评估纳曲酮（每日50毫克）在减少酒精使用方面的效用，并研究其对尽管接受了选择性5-羟色胺再摄取抑制剂（SSRI）治疗但仍未能戒酒的抑郁酗酒者抑郁症状的影响。14名年龄在18至65岁之间、患有DSM-III-R共病酒精依赖和重度抑郁症且尽管接受了抗抑郁药物治疗仍未能戒酒的门诊护理患者被纳入该研究。对患者进行了12周的随访，每周评估饮酒行为、抑郁症状、功能、酒精渴望和副作用。该研究结果表明，在存在通常诱因的情况下，酒精使用和饮酒冲动显著减少。还有一个趋势表明抑郁症状和整体功能有所改善。纳曲酮耐受性良好，治疗开始时报告有轻微副作用。
